First-pass disposition of (-)-6-aminocarbovir in rats: II. Inhibition of intestinal first-pass metabolism

Drug Metabolism and Disposition

Volumn 28, Issue 6, 2000, Pages 672-679

  Zimmerman, Cheryl L ^a   Wen, Yandong ^a,b   Remmel, Rory P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINOCARBOVIR; 9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE DEAMINASE; CARBOVIR; PENTOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISPOSITION; DRUG MIXTURE; FIRST PASS EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE WALL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE DEAMINASE; ANIMALS; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; ENZYME INHIBITORS; INTESTINES; MALE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

ADA; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034081481     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Agarwal RP (1982) Inhibitors of adenosine deaminase. Pharmacol Ther 17:399-429.
2. Al-Razzak LA, Benedetti AE, Waugh WN and Stella VJ (1990) Chemical stability of pentostatin (NSC-218321), a cytotoxic and immunosuppressant agent. Pharm Res 7:452-460.
3. Beers S, Brownell J and Vince R (1990) Prodrugs of carbovir, a selective inhibitor of HIV: Synthesis and enzymatic activation (abstract MEDI 19). Proceedings of 199th ACS National Meeting, 1990; Boston, MA.
4. Blick M, Lepe-Zuniga JL, Doig R and Quesada JR (1990) Durable complete remissions after 2′-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha. Am J Hematol 33:205-209.
5. Cedarbaum JM, Kutt H, Dhar AK, Watkins S and McDowell FH (1986) Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol 9:153-159.
6. Chinsky JM, Ramamurthy V, Fanslow WC, Ingolia DE, Blackburn MR, Shaffer KT, Higley HR, Trentin JJ, Rudolph FB, Knudsen TB and Kellems RE (1990) Developmental expression of adenosine deaminase in the upper alimentary tract of mice. Differentiation 42:172-183.
7. Deleu D, Sarre S, Ebinger G and Michotte Y (1993) The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. Naunyn Schmiedebergs Arch Pharmacol 348:576-581.
8. Ho DHW, Pincus C, Carter CJ, Benjamin RS, Freireich EJ and Bodey GP Sr (1980) Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse. Cancer Treat Rep 64: 629-633.
9. Holt PR, Tierney AR and Kotler DP (1985) Delayed enzyme expression: A defect of aging rat gut. Gastroenterology 89:1026-1034.
10. Huang S, Remmel RP and Zimmerman CL (1991) The bioavailability and nonlinear clearance of (-)-carbovir in the rat. Pharm Res 8:739-743.
11. Mendelson WB, Kuruvilla A, Watlington T, Goehl K, Paul SM and Skolnick P (1983) Sedative and electroencephalographic actions of erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA): Relationship to inhibition of brain adenosine deaminase. Psychopharmacology 79:126-129.
12. Nutt JG, Woodward WR and Anderson JL (1985) The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism. Ann Neurol 18:537-543.
13. 3H]deoxycoformycin ligand binding. J Neurochem 58:421-429.
14. Rose S, Jenner P and Marsden CD (1988) The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats. Mov Disord 3:117-25.
15. Soria I (1992) Absorption and first-pass disposition of (-)-carbovir, in the rat. (Ph.D. Thesis). University of Minnesota, Minneapolis, MN, 194 p.
16. Vince R and Brownell J (1990) Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-)-enantiomer. Biochem Biophys Res Commun 168:912-916.
17. Vince R and Hua M (1990) Synthesis and anti-HIV activity of carbocyclic 2′,3′-didehydro2′,3′-dideoxy-2,6-disubstituted purine nucleosides. J Med Chem 33:17-21.
18. Vince R, Hua M, Brownell J, Daluge S, Lee F, Shannon WM, Lavelle GC, Qualls J, Weislow OS, Kiser R, Canonico PG, Schultz RH, Narayanan VL, Mayo JG, Shoemaker RH and Boyd MR (1988) Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem Biophys Res Commun 156:1046-1053.
19. Wen Y (1995) Brain uptake and presystemic disposition of 6-aminocarbovir as a prodrug of (-)-carbovir (Ph.D. Thesis). University of Minnesota, Minneapolis, MN, 236 p.
20. Wen Y, Remmel RP, Pham PT, Vince R and Zimmerman CL (1995) Comparative brain exposure to (-)-carbovir after (-)-carbovir or (-)-6-aminocarbovir intravenous infusion in rats. Pharmi Res 12:911-915.
21. Wen Y, Remmel RP and Zimmerman CL (1999) First-pass disposition of (-)-6-aminocarbovir in rats. I. Prodrug activation may be limited by access to enzyme. Drug Metab Dispos 27:113-121.
22. Zimmerman CL, Remmel RP, Ibrahim SS, Beers SA and Vince R (1992) Pharmacokinetic evaluation of (-)-6-aminocarbovir as a prodrug for (-)-carbovir in rats. Drug Metab Dispos 20:47-51.